|
| Status |
Public on Apr 23, 2015 |
| Title |
primary_MYCN_GTML_20 |
| Sample type |
RNA |
| |
|
| Source name |
Excised Primary Tumour
|
| Organism |
Mus musculus |
| Characteristics |
model: MYCN
tissue: primary
p53: WT
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was extracted using the Qiagen AllPrep DNA/RNA mini kit (Qiagen, Hilden, Germany) according to manufacturer's instructions.Quality control was performed using an Agilent 2100 Bioanalyser.
|
| Label |
biotin
|
| Label protocol |
Approximately 200ng of each RNA was amplified and Biotinylated using the Illumina TotalPrep RNA amplification kit (Applied Biosystems, Foster City, CA. USA), with the size distribution of cRNA being assessed using the Agilent Bioanalyser.
|
| |
|
| Hybridization protocol |
Approximately 750ng of each cRNA was hybridised using the standard Illumina hybridization protocol
|
| Scan protocol |
Standard Illumina scanning protocol
|
| Description |
Mouse Model Chesler Primary - Group 3
|
| Data processing |
processed using beadarray R/Bioconductor package with quantile normalisation
|
| |
|
| Submission date |
Oct 22, 2014 |
| Last update date |
Apr 23, 2015 |
| Contact name |
Ed Schwalbe |
| E-mail(s) |
ed.schwalbe@northumbria.ac.uk
|
| Organization name |
Northumbria University
|
| Department |
Applied Sciences
|
| Street address |
Ellison Place
|
| City |
Newcastle upon Tyne |
| ZIP/Postal code |
NE1 8ST |
| Country |
United Kingdom |
| |
|
| Platform ID |
GPL6885 |
| Series (2) |
| GSE62625 |
Combined MYC and TP53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease [gene expression] |
| GSE62626 |
Combined MYC and TP53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease |
|
